TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent <i>TP53</i> mutations and FGFR pathway dysregulation.

Transl Lung Cancer Res · 2025 · PMC12541837 · PMID 41133008

Europe PMC DOI

hedged sentences

0.0900

closest p · 1.8× alpha

0.1700

boldest claim

The sentences

showed a trendP=0.09so close (0.05 < p ≤ 0.1)

Patients with high FGFR1 expression and/or FGFR1 amplification showed a trend toward poorer OS compared to those without these alterations (P=0.09; Figure 5 ).

also in 53,322 other papers

did not reach statistical significanceP=0.17not close (p > 0.1)

CPS and TPS values were numerically higher among ADCs compared to SCCs, though differences did not reach statistical significance (P=0.17 and P=0.09, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.

TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent &lt;i&gt;TP53&lt;/i&gt; mutations and FGFR pathway dysregulation.

The sentences

TTF-1 and p40 co-expression defines a distinct subtype of non-small cell lung cancer with frequent <i>TP53</i> mutations and FGFR pathway dysregulation.